This phase I study will examine the pharmacokinetics and safety of Onartuzumab (MetMAb) in chinese patients with locally advanced or metastatic solid tumors. Patients will be divided into 3 cohorts, which will each be given a different dose of MetMAb. The cohorts will be treated sequentially, starting with the lowest dose. MetMAb will be administered intravenously every 3 weeks. Patients may be treated for up to 16 cycles (21 days each) or 1 year, whichever occurs first, in the absence of disease progression.

Inclusion Criteria:

• Age >/= 18 years
• Histologically confirmed locally advanced or metastatic solid tumor that does not respond to standard treatment or for which there is no further standard treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2.
• Use of effective contraception
• Life expectancy > 3 months

Exclusion Criteria:

• Brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation, and/or patients with brain metastasis that have been receiving corticosteroids.
• Previously diagnosed and treated central nervous system (CNS) metastases or spinal cord compression that has not been clinically stable for at least 2 months.
• Treatment with anti-tumor therapy within 4 weeks before the start of study treatment, with the following exception: Patients with metastatic prostate cancer on maintenance hormonal therapy, provided they meet all other eligibility criteria.
• Current, serious or uncontrolled, systemic illness.
• Recent stroke (within the past 6 months).
• Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs).
• History of cardiovascular conditions.
• Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
• Receipt of any investigational agent, or participation in any other clinical study, within 4 weeks before the start of study treatment.
• Major surgery within 4 weeks before the start of study treatment, without complete recovery.
• Significant traumatic injury within 3 weeks before the start of study treatment (All wounds must be fully healed prior to Day 1).
• Uncontrolled excess calcium levels.
• Known human immunodeficiency virus (HIV) infection.
• Inadequate organ function
• Pregnancy